Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on Wednesday, February 5th. Analysts expect Viking Therapeutics to post earnings of ($0.28) per share for the quarter.
Viking Therapeutics Trading Up 2.6 %
Shares of VKTX stock opened at $34.32 on Wednesday. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -36.90 and a beta of 0.95. Viking Therapeutics has a twelve month low of $21.26 and a twelve month high of $99.41. The stock has a fifty day simple moving average of $43.29 and a two-hundred day simple moving average of $55.04.
Insiders Place Their Bets
In other Viking Therapeutics news, CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the completion of the sale, the chief financial officer now owns 165,259 shares of the company’s stock, valued at approximately $7,064,822.25. The trade was a 23.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brian Lian sold 194,490 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $8,314,447.50. Following the completion of the transaction, the chief executive officer now directly owns 2,366,570 shares in the company, valued at $101,170,867.50. This represents a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 301,014 shares of company stock valued at $12,920,189. Insiders own 4.70% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Analysis on Viking Therapeutics
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Recommended Stories
- Five stocks we like better than Viking Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Top Stocks Investing in 5G Technology
- What Does the Future Hold for Eli Lilly?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.